(Ibalizumab)Biosimilar Reference Antibody-GS40319

货号：GS40319

Ibalizumab is a humanized monoclonal IgG4 antibody approved for the treatment of multidrug-resistant HIV-1 infection in heavily treatment-experienced adults. It represents a first-in-class post-attachment HIV-1 inhibitor. Unlike most antiretrovirals that target viral enzymes (reverse transcriptase, integrase, protease) or the CCR5 co-receptor, ibalizumab has a unique host-directed mechanism. It binds to domain 2 of the CD4 receptor on the surface of host T cells. This binding does not block HIV-1's initial attachment to CD4 but induces conformational changes that prevent the essential post-attachment steps required for viral entry, specifically the fusion of the viral and host cell membranes. It is administered intravenously every two weeks.